UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark one)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2026
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File Number: 0-19961
ORTHOFIX MEDICAL INC.
(Exact name of registrant as specified in its charter)
Delaware
98-1340767
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
3451 Plano Parkway,
Lewisville, Texas
75056
(Address of principal executive offices)
(Zip Code)
(214) 937-2000
(Registrant's telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated filer
Accelerated filer
Non-Accelerated filer
Smaller Reporting Company
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
As of July 31, 2026, 40,732,608 shares of common stock were issued and outstanding.
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, $0.10 par value per share
OFIX
Nasdaq Global Select Market
Table of Contents
Page
PART I
FINANCIAL INFORMATION
Item 1.
Financial Statements
4
Condensed Consolidated Balance Sheets as of June 30, 2026, and December 31, 2025
Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2026, and 2025
5
Condensed Consolidated Statements of Changes in Shareholders' Equity for the three and six months ended June 30, 2026, and 2025
6
Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026, and 2025
7
Notes to the Unaudited Condensed Consolidated Financial Statements
8
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
23
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
31
Item 4.
Controls and Procedures
32
PART II
OTHER INFORMATION
Legal Proceedings
33
Item 1A.
Risk Factors
Unregistered Sales of Equity Securities and Use of Proceeds
Defaults Upon Senior Securities
Mine Safety Disclosures
Item 5.
Other Information
Item 6.
Exhibits
SIGNATURES
35
2
Forward-Looking Statements
This quarterly report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts, and projections. All statements, other than statements of historical fact, contained in this report, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," "positioned," "deliver," or "continue" or other comparable terminology. Forward-looking statements include, but are not limited to, statements about:
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties, estimates, and assumptions that are difficult to predict. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in forward-looking statements. Potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to, those set forth in Part I, Item 1A under the heading Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 10-K"); Part II, Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations of the 2025 10-K; and elsewhere throughout the 2025 10-K, and in our reports filed with the U.S. Securities and Exchange Commission (the "SEC") subsequent to the date we filed the 2025 10-K with the SEC. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement in this report speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. Except as required by law, we undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.
Trademarks
Solely for convenience, our trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as an indicator that we will not assert, to the fullest extent under applicable law, our rights thereto.
3
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Condensed Consolidated Balance Sheets
(U.S. Dollars, in thousands, except par value data)
June 30,2026
December 31,2025
(Unaudited)
Assets
Current assets
Cash and cash equivalents
$
103,810
82,025
Restricted cash
595
3,090
Accounts receivable, net of allowances of $10,563 and $8,308, respectively
135,818
135,746
Inventories
184,475
172,319
Prepaid expenses and other current assets
21,434
23,667
Total current assets
446,132
416,847
Property, plant, and equipment, net
130,757
129,399
Intangible assets, net
65,972
72,765
Goodwill
194,934
Other long-term assets
35,225
36,702
Total assets
873,020
850,647
Liabilities and shareholders’ equity
Current liabilities
Accounts payable
63,531
58,392
Current portion of finance lease liability
125
837
Other current liabilities
93,354
111,253
Total current liabilities
157,010
170,482
Long-term debt
221,591
157,391
Long-term portion of finance lease liability
12,903
17,060
Other long-term liabilities
52,336
55,677
Total liabilities
443,840
400,610
Contingencies (Note 7)
Shareholders’ equity
Common shares $0.10 par value; 100,000 shares authorized; 40,730 and 39,834 issued and outstanding as of June 30, 2026, and December 31, 2025, respectively
4,073
3,983
Additional paid-in capital
830,423
813,769
Accumulated deficit
(405,039
)
(368,333
Accumulated other comprehensive income (loss)
(277
618
Total shareholders’ equity
429,180
450,037
Total liabilities and shareholders’ equity
The accompanying notes form an integral part of these condensed consolidated financial statements.
Condensed Consolidated Statements of Operations and Comprehensive Loss
Three Months EndedJune 30,
Six Months EndedJune 30,
(Unaudited, U.S. Dollars, in thousands, except per share data)
2026
2025
Net sales
210,933
203,121
407,641
396,767
Cost of sales
61,226
63,588
118,388
135,615
Gross profit
149,707
139,533
289,253
261,152
Sales, general, and administrative
138,030
136,493
272,941
269,474
Research and development
15,944
15,934
31,264
35,700
Acquisition-related amortization, impairment, and remeasurement (Note 11)
3,867
3,109
7,618
20,854
Operating loss
(8,134
(16,003
(22,570
(64,876
Interest expense, net
(6,085
(3,950
(11,749
(8,456
Other income (expense), net
(778
5,730
(1,512
6,976
Loss before income taxes
(14,997
(14,223
(35,831
(66,356
Income tax (expense) benefit
(801
142
(875
(819
Net loss
(15,798
(14,081
(36,706
(67,175
Net loss per common share:
Basic
(0.39
(0.36
(0.90
(1.71
Diluted
Weighted average number of common shares:
40,906
39,501
40,677
39,317
Other comprehensive income (loss), before tax
Currency translation adjustment
(419
3,464
(895
5,210
Income tax expense related to other comprehensive income (loss)
—
Other comprehensive income (loss), net of tax
Comprehensive loss
(16,217
(10,617
(37,601
(61,965
Condensed Consolidated Statements of Changes in Shareholders' Equity
(Unaudited, U.S. Dollars, in thousands)
Number ofCommonSharesOutstanding
CommonShares
AdditionalPaid-inCapital
Accumulated Deficit
AccumulatedOtherComprehensive Income (Loss)
TotalShareholders’Equity
At December 31, 2025
39,834
(20,908
Other comprehensive loss, net of tax
(476
Share-based compensation expense
6,533
Common shares issued, net
548
55
(55
At March 31, 2026
40,382
4,038
820,247
(389,241
435,186
7,735
348
2,441
2,476
At June 30, 2026
40,730
At December 31, 2024
38,486
3,849
779,718
(276,141
(4,302
503,124
(53,094
Other comprehensive income, net of tax
1,746
6,469
610
61
(12
49
At March 31, 2025
39,096
3,910
786,175
(329,235
(2,556
458,294
7,824
387
38
2,808
2,846
At June 30, 2025
39,483
3,948
796,807
(343,316
908
458,347
Condensed Consolidated Statements of Cash Flows
Cash flows from operating activities
Adjustments to reconcile net loss to net cash from operating activities
Depreciation, amortization, and impairment
26,766
51,302
Inventory reserve expenses
8,010
25,393
Amortization of operating lease assets, debt costs, and other assets
2,146
2,377
Provision for expected credit losses
3,591
1,837
Deferred income taxes
432
12
14,268
14,293
Loss on disposal of fixed assets
404
581
Change in valuation of investment securities
(16
(31
Change in fair value of contingent consideration
1,618
(1,373
Other
890
(1,188
Changes in operating assets and liabilities
Accounts receivable
(4,079
5,089
(20,925
(5,890
2,144
(394
484
(9,138
(22,784
(21,763
Other long-term assets and liabilities
(77
(684
Net cash used in operating activities
(23,834
(6,752
Cash flows from investing activities
Capital expenditures
(23,308
(13,845
Other investing activities
146
Net cash used in investing activities
(23,162
(13,833
Cash flows from financing activities
Proceeds from issuance of common shares
2,626
3,054
Payments related to tax withholdings for share-based compensation
(150
(159
Payments related to finance lease obligation
(56
(375
Proceeds from credit facility
64,025
Payment of debt issuance costs and other financing activities
(24
(531
Net cash provided by financing activities
66,421
1,989
Effect of exchange rate changes on cash
(135
1,547
Net change in cash and cash equivalents
19,290
(17,049
Cash, cash equivalents, and restricted cash at the beginning of period
85,115
85,738
Cash, cash equivalents, and restricted cash at the end of period
104,405
68,689
Components of cash, cash equivalents, and restricted cash at the end of period
65,606
3,083
Noncash investing activities - Accrued purchases of capital expenditures
17,696
10,990
Noncash investing activities - Purchase of intangible assets
40
1. Business and basis of presentation
Description of the Business
Orthofix Medical Inc. (the "Company" or "Orthofix") is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company offers a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics, and enabling technologies, including the 7D FLASH Navigation System. The Company’s technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair statement have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company's Annual Report on Form 10-K for the year ending December 31, 2025. Operating results for the three and six months ended June 30, 2026, are not necessarily indicative of the results that may be expected for other interim periods or the year ending December 31, 2026.
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition; contractual allowances; allowances for expected credit losses; inventories; valuation of intangible assets; goodwill; fair value measurements, including contingent consideration; litigation and contingent liabilities; tax matters; and share-based compensation. Actual results could differ from these estimates.
2. Recently adopted accounting standards and recently issued accounting pronouncements
Recently Issued Accounting Pronouncements
Topic
Description of Guidance
Effective Date
Status of Company's Evaluation
Disclosure Improvements - Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative (Accounting Standard Update "ASU" 2023-06)
Adds interim and annual disclosure requirements to a variety of subtopics in the Accounting Standards Codification, including those focusing on accounting changes, earnings per share, debt, and repurchase agreements. The guidance will be applied prospectively. The effective date will be the date when the SEC's removal of the related disclosure requirement becomes effective, with early adoption prohibited.
Various
The Company is currently evaluating the impact this ASU may have on its consolidated financial statements.
Disaggregation of Income Statement Expenses (ASU 2024-03)
Improves financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to the financial statements at interim and annual reporting periods. The amendments are to be applied prospectively to financial statements issued for reporting periods after the effective date or retrospectively to all prior periods presented in the financial statements.
January 1, 2027
Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06)
Aligns the accounting for internal-use software with how software is developed to increase the operability of the recognition and capitalization of internal-use software costs in accordance with Subtopic 350-40. Early adoption is permitted as of the beginning of an annual reporting period. The guidance is to be applied prospectively to new software costs incurred as of the beginning of the adoption period for all projects, including in-process projects.
January 1, 2028
Narrow-Scope Requirements for Interim Reporting (ASU 2025-11)
Clarifies interim disclosure requirements and applicability of Topic 270, Interim Reporting for events since the end of the last annual reporting period that have a material impact on the entity. Early adoption is permitted and the amendments are to be applied prospectively or retrospectively to any or all periods presented in the financial statements.
Other recently issued ASUs, excluding those ASUs which have already been disclosed as adopted or described above, were assessed and determined not applicable, or are expected to have minimal impact on the Company's condensed consolidated financial statements.
9
3. Inventories
Inventories were as follows:
(U.S. Dollars, in thousands)
Raw materials
31,807
22,865
Work-in-process
63,472
63,255
Finished products
89,196
86,199
4. Leases
A summary of the Company's lease portfolio as of June 30, 2026, and December 31, 2025, is presented in the table below:
Classification
Operating leases
20,918
22,279
Finance leases
9,292
14,442
Total lease assets
30,210
36,721
Liabilities
Current
3,061
3,147
Long-term
24,220
25,413
Total lease liabilities
40,309
46,457
The Company entered into an amendment for its corporate headquarters location in Lewisville, Texas in January 2026, extending the contractual term of its lease to 2040, while also maintaining its existing lease term extension options within the agreement. Accordingly, the Company reassessed the lease classification and remeasured the lease liability based on the terms of the amendment. This resulted in a decrease in the recognized finance lease liability and finance lease right-of-use asset of approximately $4.8 million, respectively, with this decrease largely driven by an increase in the Company incremental borrowing rate.
Supplemental cash flow information related to leases was as follows:
Six Months Ended June 30,
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases
4,309
4,407
Operating cash flows from finance leases
735
401
Financing cash flows from finance leases
56
375
ROU assets obtained in exchange for lease obligations
256
11,690
28
10
5. Long-term debt
The carrying values of the Company's outstanding debt obligations as of June 30, 2026, and December 31, 2025, were as follows:
Outstanding Term Loans
Principal amount
225,000
160,000
Unamortized original debt discount
(2,447
(1,839
Unamortized debt issuance costs and lenders fees
(962
(770
Total indebtedness from outstanding term loans
Current portion of long-term debt
Total indebtedness outstanding
On November 7, 2024, the Company, as borrower, and its U.S. subsidiaries entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including Oxford, K2 HealthVentures LLC, and HSBC Ventures USA Inc. The Credit Agreement provides for a $160.0 million senior secured term loan (the "Initial Term Loan") and a $65.0 million senior secured delayed draw term loan facility (the "Term B Loan"). In addition, at Oxford's discretion, an additional $50.0 million of draw capacity is available through January 1, 2029 (the "Term C Loan" and, collectively with the Term B Loan and the Initial Term Loan, the "Credit Facilities").
On January 15, 2026, the Company borrowed $65.0 million via the Term B Loan to provide capital flexibility ahead of the expiration of the tranche. The Credit Facilities, to the extent ultimately drawn, will each mature in November 2029, following an interest-only payment period ending December 2028, and monthly amortization of principal and accrued interest between January 2029 and November 2029. The Credit Agreement contains financial covenants requiring the Company to maintain (i) a minimum level of liquidity at all times and (ii) a maximum total debt-to-EBITDA leverage ratio (measured on a quarterly basis) during the term of the facility. As of June 30, 2026, the Company was in compliance with all required financial covenants.
As of June 30, 2026, the Company had no borrowings on its available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.3 million).
6. Fair value measurements
The fair value measurements of the Company's financial assets and liabilities measured on a recurring basis were as follows:
Level 1
Level 2
Level 3
Total
Lattus Contingent Consideration
9,548
7,930
Deferred compensation plan
1,543
1,720
11,091
9,650
In connection with the merger with SeaSpine Holdings Corporation ("SeaSpine") in 2023 (the "Merger"), the Company assumed a contingent consideration obligation under a purchase agreement between SeaSpine and Lattus Spine LLC ("Lattus") executed in December 2022. Under the terms of this agreement, the Company may be required to make installment payments to Lattus (the "Lattus Contingent Consideration") at certain dates based on future net sales of certain products (the "Lateral Products").
The estimated fair value of the Lattus Contingent Consideration is determined using a Monte Carlo simulation and a discounted cash flow model requiring significant inputs which are not observable in the market. The significant inputs include assumptions related to the estimated future sales of Lateral Products, revenue risk-adjusted discount rates, revenue volatility, and discount rates matched
11
to the timing of payments. The following table provides a reconciliation of the beginning and ending balances for the Lattus Contingent Consideration measured at estimated fair value using significant unobservable inputs (Level 3):
Lattus Contingent Consideration estimated fair value at January 1
15,400
Change in fair value recognized in acquisition-related amortization, impairment, and remeasurement
Lattus Contingent Consideration estimated fair value at June 30
14,027
The estimated fair value of the Lattus Contingent Consideration as of June 30, 2026, was $9.5 million; however, the actual amount ultimately paid could be higher or lower. As of June 30, 2026, the Company classified the remaining Lattus Contingent Consideration of $9.5 million within other current liabilities.
The following table provides quantitative information related to certain key assumptions utilized within the valuation as of June 30, 2026:
Fair Value as of June 30, 2026
Unobservable inputs
Estimate
Counterparty discount rates
11.5
%
Revenue risk-adjusted discount rates
6.0
On July 1, 2026, the Company made an installment payment related to the Lattus Contingent Consideration of $5.1 million.
7. Commitments and Contingencies
Arbitration claims with former executives
In September 2023, the Company's Board of Directors (the "Board") terminated the employment of Keith Valentine, John Bostjancic, and Patrick Keran, who had served respectively as the Company’s President and Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer (collectively, the "Former Executives"). The Board’s decision followed an investigation conducted by independent outside legal counsel and directed and overseen by a committee of certain of the Company’s independent directors. At the time of termination, the Company notified each of the Former Executives that their respective terminations of employment were being made for "Cause," as such term is defined in applicable employment-related agreements (including each executive’s respective Change in Control and Severance Agreement, dated June 19, 2023 (the "CIC and Severance Agreements"). The Former Executives subsequently made claims against the Company in arbitration in the State of California, asserting breach of contract because each of them was entitled to the severance payments and other equity-based rights that would be owed to them if their respective termination had been made "without Cause" under the CIC and Severance Agreements, and further asserting damages for purported defamation, false light invasion of privacy, and deceit, as well as indemnification and advancement for attorneys’ fees.
On January 26, 2026, the arbitrator in Mr. Valentine’s matter issued a decision denying Mr. Valentine’s defamation, false light invasion of privacy, and deceit claims, and his indemnification of fees claim. Based on the evidence presented during the arbitration process, the arbitrator found that Mr. Valentine’s conduct met the legal definition of "acts of moral turpitude" and that the public statements that the Company made about Mr. Valentine in a press release and filings with the SEC subsequent to the termination of his employment were true. Although Mr. Valentine’s conduct was found to meet the legal definition of "acts of moral turpitude" for purposes of his defamation and other tort claims, and although engaging in "material acts of moral turpitude" would constitute "Cause" under the CIC and Severance Agreement, the arbitrator maintained his preliminary decision issued on October 2, 2025, finding that (i) Mr. Valentine’s conduct prior to his entry into the CIC and Severance Agreement on June 19, 2023 could not be considered for purposes of determining whether "Cause" existed under such agreement, and (ii) his conduct between that date and his termination of employment on September 11, 2023, did not amount to "Cause". As a result, the arbitrator issued an interim award to Mr. Valentine for breach of contract damages in the amount of $11.8 million, finding such amount to be equivalent to the severance and equity-based rights that Mr. Valentine would have received in a "without Cause" termination. The arbitrator also awarded accrued interest, at the pre-judgment interest rate of 10% under California law. On April 22, 2026, the Company made a payment in satisfaction of the arbitrator’s interim award plus accrued interest, in the amount of $14.8 million. On June 24, 2026, the arbitrator issued his final award. The final award (i) confirmed the amounts in the interim award (which were paid by the Company
on April 22, 2026), and (ii) awarded an additional $1.1 million to Mr. Valentine for attorneys' fees, costs, and expenses, which the Company has accrued as of June 30, 2026.
On April 15, 2026, Mr. Keran’s arbitration claims were settled for $4.25 million. On April 22, 2026, the Company and Mr. Bostjancic entered into a settlement agreement covering all of Mr. Bostjancic’s claims, in the amount of $4.25 million. Payments were made to each of Mr. Keran and Mr. Bostjancic in the amount of $4.25 million, respectively, in the second quarter of 2026.
In addition to the Former Executives’ arbitration claims, in September 2024, Messrs. Valentine, Bostjancic and Keran filed an action in California State Court against former director and interim CEO Catherine Burzik and current director Wayne Burris, seeking relief for, among other things, alleged defamation, false light invasion of privacy, intentional misrepresentation, false promise, and tortious interference with contract. Mr. Bostjancic dismissed his claims in this action in connection with his settlement agreement. The Company disagrees with the allegations contained in the action against Ms. Burzik and Mr. Burris and will continue vigorously defending the asserted claims. The Company currently cannot reasonably estimate a possible loss, or range of loss, that may arise from the action.
Securities class action complaints
On August 21, 2024, a securities class action complaint captioned Bernal v. Orthofix Medical Inc., et al., Case No. 24-cv-00690, was filed in the United States District Court for the Eastern District of Texas (the "Bernal Complaint"). The plaintiff, a purported Company shareholder, alleges through the complaint violations of Sections 10(b) and 20(a) of the Exchange Act, and SEC Rule 10b-5 promulgated thereunder, and names as defendants the Company and the following former Company directors and officers: Jon Serbousek (former director and former President and Chief Executive Officer), Keith Valentine (former director and former President and Chief Executive Officer), John Bostjancic (former Chief Financial Officer), and Patrick Keran (former Chief Legal Officer). The complaint alleges that the Company made, and the named former directors and officers caused the Company to make, materially false and misleading statements between October 11, 2022, and September 12, 2023, that, according to the complaint, falsely assured the market of Messrs. Valentine, Bostjancic, and Keran's respective commitments to, among other things, ethical and legal standards and corporate responsibility.
On September 6, 2024, a securities class action complaint captioned O'Hara v. Orthofix Medical Inc., et al., Case No. 24-cv-01593, was filed in the United States District Court for the Southern District of California (the "O'Hara Complaint"). The plaintiff, a purported former shareholder of SeaSpine at the time of the Merger, alleges through the complaint violations of Sections 11, 12 and 15 of the Securities Act, and names most of the same defendants as the Bernal Complaint, as well as certain additional current and/or former Company directors and officers. The complaint makes similar assertions to the Bernal complaint, and alleges that the Company's registration statement on Form S-4 filed in 2022 in connection with the Merger, as well as related written and oral offering materials, contained untrue statements of material fact and material omissions, including, among other things, with respect to the effectiveness of the Company's internal controls. On November 26, 2024, the O'Hara Complaint was transferred to the Eastern District of Texas, and on December 11, 2024, the O'Hara Complaint was consolidated with the Bernal Complaint. On April 17, 2025, the plaintiffs filed an amended complaint in the consolidated action, captioned In re Orthofix Medical Inc. Securities Litigation, with substantially the same allegations contained in the Bernal Complaint and the O'Hara Complaint. The consolidated case is captioned In re Orthofix Medical Inc. Securities Litigation, Case No. 24-cv-00690 and is pending in the Eastern District of Texas. The Company and the individual defendants moved to dismiss the amended complaint on May 15, 2025. On March 9, 2026, the Court granted defendants’ motion to dismiss the plaintiffs’ claims under the Exchange Act (but not those under the Securities Act), finding that (i) all but one of the Company’s statements at issue were immaterial as a matter of law, and (ii) no statements caused loss. The Court provided the plaintiffs with leave to amend their complaint to address pleading deficiencies, and plaintiffs filed an amended complaint on April 8, 2026, which the Company and the individual defendants moved to dismiss on May 8, 2026.
On October 28, 2024, a derivative shareholder complaint was filed against certain of the Company's current and former officers and directors alleging derivative liability for the allegations made in the two complaints noted above. On December 18, 2024, a second derivative shareholder complaint was filed with the same allegations made in the first derivative shareholder complaint. On March 21, 2025, the two derivative shareholder complaints were consolidated into one case.
The Company disagrees with the legal claims asserted in these complaints and is vigorously defending them. Due in part to the preliminary nature of these three matters, the Company currently cannot reasonably estimate a possible loss, or range of loss, that may arise from the respective complaints.
Commitments
As a result of the Merger, the Company became party to agreements with certain distributor partners that provide the Company with an option to purchase, and an option for those partners to require the Company to purchase, the distribution business of those partners at specified future dates. At such time, the Company or distributor may (in certain cases, subject to satisfying certain
13
conditions) submit written notice to the other of its intention to exercise its rights and initiate or require the purchase. Upon receipt of the written notice, the Company and the distributor will work in good faith to consummate the purchase, provided that the distributor meets the required conditions of such purchase option. Under certain of these agreements, the purchase price would be paid in shares of the Company's common stock, whereas for others, the purchase price can be paid in cash or shares, at the Company's option. Based on the closing price of the Company's common stock as of June 30, 2026, assuming the options under all the relevant agreements were exercised, the estimated total number of shares the Company would issue under these agreements was approximately 0.5 million shares for agreements that must be settled in shares of the Company's stock. The Company has received notification from one such distributor, who has notified the Company of its decision to exercise its buyout option. The Company is currently in negotiations with this distributor with respect to the conditions of a potential acquisition, the consummation of which may be deferred to a future date.
Italian Medical Device Payback (IMDP)
In 2015, the Italian Parliament introduced rules for entities that supply goods and services to the Italian National Healthcare System. A key provision of the law is a 'payback' measure, requiring medical device companies in Italy to make payments to the Italian government if medical device expenditures exceed regional maximum ceilings. Companies are required to make payments equal to a percentage of expenditures exceeding maximum regional caps.
In the third quarter of 2022, the Italian Ministry of Health provided guidelines to the Italian regions and provinces on seeking payback of expenditure overruns relating to the 2015 through 2018 calendar years. Since receiving the guidelines, several regions and provinces have requested payment from affected medical device companies, including the Company. The Company has taken legal action to dispute the legality of such measures. In July 2024, the Italian Constitutional Court issued two judgments following public hearings on the matter held in May 2024. These judgments (i) declared the payback system itself as constitutionally legitimate and (ii) extended previously communicated reductions in the payback liability for certain fiscal years to all medical device companies, regardless of whether or not they had waived their legal claims on the matter.
The Company accounts for the estimated cost of the IMDP as sales, general, and administrative expense and periodically reassesses the liability based upon current facts and circumstances. As a result, the Company recorded expenses of $0.4 million and $0.7 million for the three and six months ended June 30, 2026, respectively, and expenses of $0.3 million and $0.6 million for the three and six months ended June 30, 2025. As of June 30, 2026, the Company has accrued $11.0 million related to the IMDP, which it has classified within other long-term liabilities; however, the actual liability could be higher or lower than the amount accrued once all legal proceedings are resolved and upon further clarification of the IMDP by the Italian authorities.
8. Accumulated other comprehensive income (loss)
The components of and changes in accumulated other comprehensive income (loss) were as follows:
CurrencyTranslationAdjustments
Neo Medical Convertible Loan
Accumulated OtherComprehensive Income (Loss)
Balance at December 31, 2025
846
(228
Other comprehensive loss
Income taxes
Balance at June 30, 2026
(49
9. Revenue recognition and accounts receivable
Revenue recognition
The Company has two reporting segments: Global Spine and Global Limb Reconstruction. Within the Global Spine reporting segment, there are two product categories: (i) Therapeutic Solutions (formerly Bone Growth Therapies), and (ii) Spinal Implants, Biologics, and Enabling Technologies.
14
The tables below present net sales by product category and reporting segment:
Three Months Ended June 30,
Change
Therapeutic Solutions
64,152
62,573
2.5
Spinal Implants, Biologics, and Enabling Technologies
109,091
107,251
1.7
Global Spine
173,243
169,824
2.0
Global Limb Reconstruction
37,690
33,297
13.2
3.8
121,926
117,623
3.7
215,169
216,037
-0.4
337,095
333,660
1.0
70,546
63,107
11.8
2.7
Product sales and marketing service fees
The table below presents product sales and marketing service fees, which are both components of net sales:
Product sales
199,979
191,395
386,095
373,028
Marketing service fees
10,954
11,726
21,546
23,739
Marketing service fees are received from MTF Biologics ("MTF") based on total sales of biologic tissues and relate solely to the Biologics product category within the Global Spine reporting segment, whereas product sales primarily consist of the sale of Therapeutic Solutions, Spinal Implants, non-MTF sourced Biologics, Enabling Technologies, and Global Limb Reconstruction products. As MTF is the single supplier for certain allografts in the Company's Biologics portfolio, which are derived from deceased donors for their bone grafts and living donors for their amnion grafts, any event or circumstance that would impact MTF's continued access to donors or the Company's ability to market these tissues may adversely impact the Company's financial results.
Accounts receivable and related allowances
The following table provides the detail of changes in the Company's allowance for expected credit losses for the three and six months ended June 30, 2026, and 2025:
Allowance for expected credit losses beginning balance
8,990
8,602
8,308
7,418
Current period provision for expected credit losses
2,872
779
Write-offs charged against the allowance and other
(1,254
(747
(1,259
(758
Effect of changes in foreign exchange rates
(45
275
412
Allowance for expected credit losses ending balance
10,563
8,909
10. Business segment information
The Company's operations are managed through two reporting segments: Global Spine and Global Limb Reconstruction. These reporting segments represent the operating segments for which the President and Chief Executive Officer, who is also the Chief Operating Decision Maker (CODM), reviews financial information and makes resource allocation decisions among businesses. The primary metric used by the CODM in managing the Company is adjusted earnings before interest, tax, depreciation, and amortization ("adjusted EBITDA", a non-GAAP financial measure). Adjusted EBITDA represents earnings before interest income (expense), income taxes, depreciation and amortization, and excludes the impact of share-based compensation and long-term
15
incentive plan expense; gains and losses related to changes in foreign exchange rates; charges related to the Merger and other strategic investments; restructuring costs and impairments related to the discontinuation of the M6 product lines (as defined in Note 15); acquisition-related fair value adjustments; gains and/or losses on investments; litigation and investigation charges; refunds associated with the Employee Retention Credit established by the Coronavirus Aid, Relief, and Economic Security Act; and certain costs associated with employee transitions.
Corporate activities are comprised of operating expenses not directly identifiable within the two reporting segments, such as human resources, finance, legal, and information technology functions. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information.
The Global Spine reporting segment offers two primary product categories: (i) Therapeutic Solutions and (ii) Spinal Implants, Biologics, and Enabling Technologies.
The Therapeutic Solutions product category manufactures, distributes, and provides support services for market-leading bone growth stimulation devices that enhance bone fusion. These Class II medical devices with special controls are indicated as an adjunctive, noninvasive treatment to improve fusion success rates in the cervical and lumbar spine as well as a therapeutic treatment for non-spinal, appendicular fractures, treating both fresh or nonunion fractures. These products are sold almost exclusively in the U.S., using distributors and direct sales representatives to provide these devices to healthcare providers and their patients.
Spinal Implants, Biologics, and Enabling Technologies is comprised of (i) a broad portfolio of spine fixation implant products used in surgical procedures of the spine, (ii) one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments, and (iii) image-guided surgical solutions to facilitate degenerative, minimally invasive, and complex surgical procedures. Spinal Implants, Biologics, and Enabling Technologies products are sold through a network of distributors and sales representatives to hospitals and healthcare providers on a global basis for Spinal Implants and Enabling Technologies, and primarily within the U.S. for Biologics.
The Global Limb Reconstruction reporting segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. This reporting segment specializes in the design, development, and marketing of external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. The Company sells these products worldwide through a global network of distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers.
16
The following table presents adjusted EBITDA, the primary metric used in managing the Company, by reporting segment:
Three Months Ended June 30, 2026
Six Months Ended June 30, 2026
Segment revenues
Less:
Non-GAAP Cost of sales
44,561
14,664
59,225
87,403
29,279
116,682
Non-GAAP Sales, general, and administrative
100,992
22,088
123,080
199,013
42,289
241,302
Non-GAAP Research and development
11,528
14,611
22,925
6,082
29,007
Other segment expenses
63
20
83
322
958
1,280
Add:
Non-GAAP Depreciation, amortization, and share-based compensation expense
9,490
3,311
12,801
18,558
6,539
25,097
Segment Adjusted EBITDA
25,589
1,146
26,735
45,990
(1,523
44,467
Reconciling items:
Corporate operating expenses
6,597
14,635
6,085
11,749
Depreciation and amortization
13,273
Share-based compensation and long-term incentive plan expense
7,945
14,583
Foreign exchange impact
746
1,646
SeaSpine merger-related costs
572
503
Restructuring costs and impairments related to M6 product lines
1,085
1,338
Strategic investments
634
1,584
Acquisition-related fair value adjustments
868
Interest and loss on investments
Litigation and investigation costs
2,185
5,101
Employee Retention Credit
(951
Employee transition costs
1,742
17
Three Months Ended June 30, 2025
Six Months Ended June 30, 2025
Segment Revenues
42,811
12,266
55,077
87,398
24,137
111,535
97,169
17,990
115,159
189,708
35,911
225,619
11,761
2,674
14,435
23,384
5,526
28,910
Other segment expenses (benefits)
2,464
2,470
6,907
(169
6,738
10,814
2,124
12,938
19,686
4,756
24,442
26,433
2,485
28,918
45,949
2,458
48,407
8,273
16,331
3,950
8,456
16,871
(2,751
(3,795
4,886
6,016
3,354
15,480
353
(763
4,029
7,071
(2,854
The following table presents depreciation, amortization, and impairment by reporting segment:
9,986
14,851
20,204
46,753
2,807
1,419
5,585
3,355
Corporate
480
601
977
1,194
18
Geographical information
The table below presents net sales by geographic destination for each reporting segment and for the consolidated Company:
U.S.
159,990
161,850
312,407
314,553
International
13,253
7,974
24,688
19,107
Total Global Spine
10,043
9,888
18,954
18,866
27,647
23,409
51,592
44,241
Total Global Limb Reconstruction
Consolidated
170,033
171,738
331,361
333,419
40,900
31,383
76,280
63,348
The following data includes net sales by geographic area:
Italy
6,003
5,646
11,906
10,699
France
3,266
3,184
5,898
5,809
United Kingdom
3,694
3,118
7,567
6,155
Germany
2,315
2,265
4,485
4,473
Brazil
1,918
988
2,952
2,123
Others
23,704
16,182
43,472
34,089
The following data includes property, plant, and equipment by geographic area:
116,655
114,483
9,434
9,893
1,008
1,360
3,660
3,663
19
11. Acquisition-related amortization, impairment, and remeasurement
Acquisition-related amortization, impairment, and remeasurement consists of (i) amortization and impairment related to intangible assets acquired through business combinations or asset acquisitions and (ii) remeasurement of any related contingent consideration arrangements. Components of acquisition-related amortization, impairment, and remeasurement are as follows:
Amortization and impairment of acquired intangibles
2,999
3,872
6,000
22,227
Changes in fair value of contingent consideration
12. Share-based compensation
Components of share-based compensation expense are as follows:
462
468
793
929
6,864
6,915
12,722
12,564
409
441
753
800
Stock options
1,857
1,594
3,088
2,463
Market-based stock options
90
592
277
1,238
Time-based restricted stock units
3,581
3,528
6,466
6,522
Market-based / performance-based restricted stock units
1,829
1,650
3,623
3,070
Stock purchase plan
378
460
814
1,000
During the three months ended June 30, 2026, and 2025, the Company issued 0.3 million and 0.4 million shares, respectively, of common stock related to stock purchase plan issuances, stock option exercises, and the vesting of restricted stock units. During the six months ended June 30, 2026, and 2025, the Company issued 0.9 million and 1.0 million shares, respectively, of common stock related to stock purchase plan issuances, stock option exercises, and the vesting of restricted stock units.
13. Income taxes
Generally, income tax provisions for interim periods are based on an estimated annual income tax rate, adjusted for discrete tax items, with any changes affecting the estimated annual effective tax rate recorded in the interim period in which the change occurs. Due to losses in the Company's U.S., Canadian and Italian operations for which no tax benefit is recognized, the Company determined the estimated annual effective tax rate method would not provide a reliable estimate of the Company's overall annual effective tax rate. As such, the Company has calculated the tax provision using the actual effective rate for the six months ended June 30, 2026. Due to the impact of temporary differences on the Company's current U.S. tax liability for which no deferred tax benefit is recognized, the Company's effective tax rate may vary in future quarters.
For the three months ended June 30, 2026, and 2025, the effective tax rate was (5.3%) and 1.0%, respectively. For the six months ended June 30, 2026, and 2025, the effective tax rate was (2.4%) and (1.2%), respectively. The primary factors affecting the Company's effective tax rate for the three and six months ended June 30, 2026, were certain losses for which no tax benefit is recognized and tax amortization on certain acquired intangibles.
14. Earnings per share (EPS)
For the three and six months ended June 30, 2026, no adjustments were made to net income for purposes of calculating basic and diluted EPS under the treasury stock method. The following is a reconciliation of the weighted average shares used in diluted EPS computations.
(Unaudited, In thousands)
Weighted average common shares-basic
Effect of dilutive securities
Unexercised stock options and stock purchase plan
Unvested restricted stock units
Weighted average common shares-diluted
There were 9.0 million and 8.7 million weighted average outstanding options, time-based restricted stock units, performance-based stock units, and market-based stock units not included in the diluted EPS computation for the three months ended June 30, 2026, and 2025, respectively, and 8.6 million and 8.4 million weighted average outstanding options, time-based restricted stock units, performance-based stock units, and market-based stock units not included in the diluted EPS computation for the six months ended June 30, 2026, and 2025, respectively, because either (i) inclusion of these awards was anti-dilutive, or (ii) for performance-based stock units and market-based stock units, all necessary conditions had not been satisfied by the end of the respective period.
15. Discontinuation of M6 product lines
In February 2025, the Company announced the discontinuation of its M6-C artificial cervical disc and M6-L artificial lumbar disc product lines (together, the "M6 artificial discs" or "M6 product lines") in order to allocate associated resources and investment to more profitable growth opportunities. Financial results for the Company's M6 product lines continue to be presented within the Company's consolidated statements of operations and comprehensive loss. A summary of impairment charges recognized during the three and six months ended June 30, 2025, and the associated financial statement lines in which such costs were recognized is shown in the table below. All such changes are included within the Company's Global Spine reporting segment. All related inventory; property, plant, and equipment; and intangible asset balances were fully impaired in the prior year; therefore, there were no further impairments recorded on these assets in the current year.
Financial Statement Line Item
Inventory reserve charges
2,548
11,251
Impairment of property, plant, and equipment
Operating expenses
608
6,834
Impairment of developed technology intangible asset
Acquisition-related amortization, impairment, and remeasurement
14,097
Loss on M6 inventories and long-lived assets held for sale
3,156
32,182
16. Subsequent Events
Centers for Medicare & Medicaid Services fee schedule updates
On April 16, 2026, the U.S. Food and Drug Administration (“FDA”) issued a final order reclassifying non-invasive bone growth stimulators from Class III to Class II devices. Following that order, the Centers for Medicare & Medicaid Services (“CMS”) modified certain billing requirements and Medicare fee schedule treatment applicable to non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748 and E0760 (the “Devices”) for dates of service on or after May 18, 2026.
On July 1, 2026, CMS issued revised guidance that withdrew those changes and directed that Devices furnished on or after May 18, 2026, be processed and paid consistent with the treatment in effect prior to the FDA reclassification. Based on these developments, the Company currently expects average Medicare reimbursement for these codes will return to the rates in effect prior to May 18, 2026.
21
Lattus Contingent Consideration Payment
On July 1, 2026, the Company made an installment payment related to the Lattus Contingent Consideration of $5.1 million. See Note 6 for further discussion of the Company’s obligations in relation to the Lattus Contingent Consideration.
22
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of Orthofix Medical Inc.'s (sometimes referred to as the "Company," "we," "us" or "our") financial condition and results of operations should be read in conjunction with the discussion under the heading "Forward-Looking Statements" and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.
Executive Summary
We are a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, we offer a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH Navigation System. Our technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients. Learn more at Orthofix.com and follow us on LinkedIn. Information included on our website is not incorporated into, nor does it otherwise create a part of, this report.
Notable financial metrics in the second quarter of 2026 and recent achievements include the following:
Results of Operations
The following table provides certain items in our condensed consolidated statements of operations as a percent of net sales:
2026(%)
2025(%)
100.0
29.0
31.3
34.2
71.0
68.7
65.8
65.5
67.3
66.9
67.9
7.6
7.8
7.7
9.0
1.8
1.5
1.9
5.3
(3.9
(7.9
(5.5
(16.4
(7.5
(6.9
(9.0
(16.9
Net Sales by Product Category and Reporting Segment
Our operations are managed through two reporting segments: Global Spine and Global Limb Reconstruction. The following tables provide net sales by product category and reporting segment:
(Unaudited, U.S. Dollars, in millions)
ConstantCurrencyChange
64.2
62.6
Spinal Implants, Biologics and Enabling Technologies*
109.0
104.8
4.0
Global Spine*
173.2
167.4
3.5
37.7
33.3
11.0
Pro forma net sales*
210.9
200.7
5.1
4.7
Impact from discontinuation of M6 product lines
0.0
2.4
(97.4
%)
(97.5
Reported net sales
203.1
121.9
117.6
214.9
209.1
336.8
326.7
3.1
3.0
70.5
63.1
7.2
407.3
389.8
4.5
0.3
6.9
(95.3
(95.6
407.6
396.7
* Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of its M6-C artificial cervical disc and M6-L artificial lumbar disc product lines (together, the "M6 artificial discs" or "M6 product lines"). Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company's pro forma net sales to its reported figures under U.S. GAAP. The Company's reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines.
Global Spine offers the following product categories:
Three months ended June 30, 2026 compared to 2025
Net sales of $173.2 million, an increase of $3.4 million or 2.0% on a reported basis
24
Six months ended June 30, 2026 compared to 2025
Net sales of $337.1 million, an increase of $3.4 million or 1.0% on a reported basis
Global Limb Reconstruction offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. Global Limb Reconstruction sells its products through a global network of distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers.
Net sales of $37.7 million, an increase of $4.4 million or 13.2% on a reported basis and 11.0% on a constant currency basis
Net sales of $70.5 million, an increase of $7.4 million or 11.8% on a reported basis and 7.2% on a constant currency basis
25
Gross Profit
% Change
(3.7
(12.7
7.3
10.8
Gross margin
2.3
Gross profit increased $10.2 million
Gross profit increased $28.1 million
Sales, General, and Administrative Expense
1.1
1.3
As a percentage of net sales
65.4
67.2
(1.8
67.0
(0.9
Sales, general, and administrative expense increased $1.5 million
Sales, general, and administrative expense increased $3.5 million
Research and Development Expense
0.1
(12.4
(0.2
(1.3
26
Research and development expense was relatively consistent with the prior year period, as increased personnel-related costs were substantially offset by lower nonrecurring charges recognized in the prior year
Research and development expense decreased $4.4 million
Acquisition-related Amortization, Impairment, and Remeasurement
24.4
(63.5
5.2
(3.3
Acquisition-related amortization, impairment, and remeasurement consists of (i) amortization and impairment related to intangible assets acquired through business combinations or asset acquisitions and (ii) remeasurement of related contingent consideration arrangements, which are recognized immediately upon acquisition.
Acquisition-related amortization, impairment, and remeasurement increased $0.8 million
Acquisition-related amortization, impairment, and remeasurement decreased $13.2 million
Non-operating Income and Expense
54.1
38.9
(113.6
(121.7
27
Interest expense, net increased $2.1 million
Other income (expense), net decreased $6.5 million
Interest expense, net increased $3.3 million
Other income (expense), net decreased $8.5 million
Income Taxes
Income tax expense (benefit)
801
(142
(664.1
875
819
6.8
Effective tax rate
(5.3
(6.3
(2.4
(1.2
Liquidity and Capital Resources
Cash, cash equivalents, and restricted cash at June 30, 2026, totaled $104.4 million compared to $85.1 million at December 31, 2025. The following table presents the net change in cash, cash equivalents, and restricted cash for the six months ended June 30, 2026, and 2025, respectively:
(17,082
(9,329
64,432
(1,682
36,339
The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities:
(9,463
Free cash flow
(47,142
(20,597
(26,545
Operating Activities
Cash flows from operating activities decreased $17.1 million
29
Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 59 days as of June 30, 2026, compared to 58 days as of June 30, 2025 (calculated using second quarter net sales and ending accounts receivable). Inventory turns decreased to 1.3 times as of June 30, 2026 compared to 1.5 times as of June 30, 2025 (calculated using trailing twelve-month cost of goods sold and ending net inventories).
Investing Activities
Cash flows used in investing activities increased $9.3 million
Financing Activities
Cash flows from financing activities increased $64.4 million
Credit Facilities
On November 7, 2024, we entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party thereto, including Oxford, K2 HealthVentures LLC, and HSBC Ventures USA Inc. Certain of our foreign subsidiaries joined the Credit Agreement as either a borrower or guarantor shortly after the signing date. The Credit Agreement provides for a $160.0 million senior secured term loan (the "Initial Term Loan") and a $65.0 million senior secured delayed draw term loan facility (the "Term B Loan") which Term B Loan was fully funded on January 15, 2026. In addition, at Oxford's discretion, an additional $50.0 million of draw capacity is available through January 1, 2029 (the "Term C Loan" and, together with the Term B Loan, the "Delayed Draw Term Loans" and collectively with the Initial Term Loan, the "Credit Facilities").
The Initial Term Loan and Delayed Draw Term Loans, to the extent ultimately drawn, will each mature in November 2029, following an interest-only payment period ending December 2028, and monthly amortization of principal and accrued interest between January 2029 and November 2029.
The Initial Term Loan and Delayed Draw Term Loans, to the extent ultimately drawn, are subject to, among other conditions, our continued compliance with a pro-forma total debt-to-EBITDA leverage ratio of less than 4.0x. EBITDA is a non-GAAP financial measure which represents earnings before interest income (expense), income taxes, depreciation, amortization, and other negotiated addbacks and adjustments.
The Credit Agreement contains financial covenants requiring us to maintain a minimum level of liquidity at all times and to maintain a maximum total debt-to-EBITDA leverage ratio (measured on a quarterly basis) during the term of the facility. As of June 30, 2026, we were in compliance with all required financial covenants.
As of June 30, 2026, we had $225.0 million of outstanding borrowings under the Credit Agreement related to the Initial Term Loan and the Term B Loan. We have not made any borrowings under the Term C Loan as of June 30, 2026.
As of June 30, 2026, we had no borrowings on our available lines of credit in Italy, which provide up to an aggregate amount of €5.5 million ($6.3 million).
For information regarding contingencies, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.
Under the terms of a contingent consideration obligation in a purchase agreement assumed in the Merger, we may be required to make installment payments to Lattus (the "Lattus Contingent Consideration") at certain dates based on future net sales of certain
30
products (the "Lateral Products"). The estimated fair value of the Lattus Contingent Consideration as of June 30, 2026, was $9.5 million. The actual amount ultimately paid could be higher or lower than the estimated fair value of the Lattus Contingent Consideration. As of June 30, 2026, we classified the remaining Lattus Contingent Consideration liability of $9.5 million within other current liabilities.
On July 1, 2026, we made an installment payment related to the Lattus Contingent Consideration of $5.1 million. For additional discussion of this matter, see Note 6 of the Notes to the Unaudited Condensed Consolidated Financial Statements.
Off-balance Sheet Arrangements
As of June 30, 2026, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.
Contractual Obligations
There have been no material changes in any of our material contractual obligations as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 10-K").
Critical Accounting Estimates
Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are described in Item 7 of our 2025 10-K. There have been no significant changes to our critical accounting estimates during the quarter covered by this report.
See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued or adopted accounting pronouncements.
Non-GAAP Financial Measures
We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP financial measures used to supplement information regarding the performance and underlying trends of our business operations to facilitate comparisons to historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their U.S. GAAP results with non-GAAP financial measures.
The non-GAAP financial measures used in this filing may have limitations as analytical tools and should not be considered in isolation or as a replacement for U.S. GAAP financial measures. Some limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.
Constant Currency
Constant currency is calculated by using foreign currency rates from the comparable, prior year period to present net sales at comparable rates. Constant currency can be presented for numerous U.S. GAAP measures but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.
Free Cash Flow
Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Management uses free cash flow as an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our market risks as disclosed in our 2025 10-K.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2026. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2026.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
For information regarding legal proceedings, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein, which is incorporated by reference into this Part II, Item 1.
Item 1A. Risk Factors
The U.S. Food and Drug Administration's ("FDA") reclassification of bone growth stimulator devices from Class III to Class II may increase competition and adversely affect our future sales.
We offer the market‑leading bone growth stimulation platform and are the only company to provide both pulsed electromagnetic field (PEMF) and low‑intensity pulsed ultrasound (LIPUS) bone healing solutions. Historically, our bone growth therapy products were regulated by the FDA as Class III medical devices, subject to the FDA’s rigorous premarket approval (PMA) requirements.
The FDA has reclassified bone growth stimulator devices from Class III to Class II, subject to "special controls." These special controls include requirements for clinical data, specific non-clinical performance and biocompatibility data, and labeling, in addition to the Class II requirement that new devices demonstrate substantial equivalence to a legally marketed predicate device. While these controls are intended to provide reasonable assurance of safety and effectiveness, the Class II regulatory pathway is generally less onerous, time‑consuming, and costly than the PMA process applicable to Class III devices.
As a result of this reclassification, competitors may be able to enter the market more readily by obtaining FDA clearance for bone growth stimulator devices that are substantially equivalent to existing products. Increased market entry could lead to heightened competition, pricing pressure, and greater marketing and promotional activity by competitors, which may reduce demand for our products or erode our market share.
Although we believe our clinical data, dual‑technology platform, and brand recognition differentiate our products, we may be required to increase investments in research and development, clinical studies, sales, marketing, and post‑market surveillance to maintain our competitive position. Any such increased costs, or a failure to effectively compete in a more crowded market, could adversely affect our revenues, margins, and results of operations.
Other than as disclosed above, there have been no material changes from the risk factors disclosed in "Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
We have not made any repurchases of our common stock during the second quarter of 2026.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Item 5. Other Information
On May 29, 2026, Patrick Fisher, President, Global Biologics and Limb Reconstruction, adopted a Rule 10b5-1 Trading Plan. Mr. Fisher’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of August 31, 2027, or the sale of all shares subject to the plan, provides for the sale of up to 1,800 shares of common stock pursuant to the terms of the plan. Mr. Fisher’s 10b5-1 Trading Plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Other than as discussed above, during the last fiscal quarter, none of our other directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any "non-Rule 10b5-1 trading arrangement."
Item 6. Exhibits
31.1*
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2*
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
32.1#
Section 1350 Certifications of each of the Chief Executive Officer and Chief Financial Officer.
10.1
Amendment No. 5 to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan (Filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed June 11, 2026, and incorporated herein by reference).
101.INS*
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH*
Inline XBRL Taxonomy Extension Schema Document.
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
* Filed herewith.
# Furnished herewith.
34
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: August 5, 2026
By:
/s/ MASSIMO CALAFIORE
Name:
Massimo Calafiore
Title:
President and Chief Executive Officer
/s/ JULIE ANDREWS
Julie Andrews
Chief Financial Officer